European Medicines Agency re-org
This article was originally published in The Tan Sheet
A major re-organization of the EU agency streamlines human drug pre- and post-authorization activities into one unit, creates a patient health protection unit and designates a group to manage product data and documentation, the agency announces Dec. 8. The changes respond to increased responsibilities proposed in legislation, the agency said. The regulator, which dropped its acronym EMEA because the second "e" confused stakeholders, plans to launch in early 2010 a redesigned Web site with improved search and navigation functions
You may also be interested in...
Vacancies Reform Act requires individual in an acting position to step down in order to be nominated to the permanent post but there are exceptions. Andrew von Eschenbach retained acting title during his nomination in 2006.
To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.